GW Pharmaceuticals, PLC is a company that specializes in the researching, manufacturing, and commercializing of prescription medicines that are cannabinoid-based with controlled substances, and plant-based pharmaceutical products that meet the needs of patients in a wide range of therapeutic conditions. GW Pharmaceuticals is listed in the NASDAQ Global Market under the symbol GWPH. It is also listed on AIM, a market of the London Stock Exchange.
The biopharmaceutical company, based in the United Kingdom, maintains internal control over every aspect of the development process of their cannabinoid products, from botanical research and drug formulation, to clinical trials and regulatory affairs.
Ever since the company was founded in 1998, GW Pharmaceuticals has focused on bringing novel prescription medicines to the market, providing patients suffering from serious conditions with valuable medicines that would truly make a difference in their quality of life. GW aims to maximize the value of its products and shareholder returns through rapid economical product development, addressing the needs of the market, and creating commercial partnerships.
GW Pharmaceuticals strives to maintain its position as a world leader in cannabinoid science, as it has developed an international network comprised of the industry’s most established scientists over the years. In 2007, GW and Otsuka collaborated, paving the way for the substantial expansion of the company’s early cannabinoid research activities. The two companies have worked together to research on cannabinoids as potential treatments for disorders of the central nervous system. The company’s in-house program also researches cannabinoids being used as treatments for metabolic disorders such as Type 2 diabetes.
GW’s lead product is Sativex, a treatment for symptom improvement of patients suffering from moderate to severe spasticity due to Multiple Sclerosis. Sativex is currently recommended for approval or already approved for use in 24 countries worldwide. It is currently in Phase III clinical development as treatment for cancer pain.
GW Pharmaceuticals, PLC is licensed to work with controlled substances for purposes of medical research. It continues to focus on its product portfolio of cannabinoid-based medicines in order to meet the needs of patients in an extensive range of medical indications.
Yahoo! Finance: GWPH News
Latest Financial News for GWPH
Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood's sickle cell disease drug Oxbryta posted $14.1 million in net sales.
After netting nearly $1 billion in profits in 2019, cannabis short sellers got off to a strong start in 2020 as well. However, cannabis stocks have taken off in recent weeks, and cannabis short sellers are feeling the pain.What HappenedS3 Partners analyst Ihor Dusaniwsky said Thursday that cannabis short sellers are down $641 million in the month of May, and their year-to-date profits are down to just $180.1 million.Dusaniwsky said S3's portfolio of 240 U.S. and Canada-listed cannabis stocks currently has $2.8 billion in total short interest. In the past week, Dusaniwsky said short sellers have added $76 million to their positions.To make matters worse for cannabis short sellers, borrow fees have been on the rise. Dusaniwsky said average borrow fees for the top 20 most shorted cannabis stocks are up 12.8% over the past month to 32.1%. Cannabis short sellers are now paying more than $2.55 million in daily financing cost.Don't miss this opportunity to connect with THE cannabis movers and shakers from across the globe during Benzinga's first Virtual Cannabis Capital Conference on June 1.Most Shorted Cannabis Stocks Here are the five most heavily shorted cannabis stocks today by short interest, according to S3: * Canopy Growth Corp (NYSE: CGC), $913.7 million. * GW Pharmaceuticals PLC (NASDAQ: GWPH), $656.1 million. * Aurora Cannabis Inc (NYSE: ACB), $186.8 million. * Cronos Group Inc (NASDAQ: CRON), $307.3 million. * Aphria Inc (NYSE: APHA), $143.5 million.Dusaniwsky said traders looking for the most likely short squeeze candidates should focus on stocks with the highest borrow fees that have generated the biggest losses for short sellers year to date."Mark-to-market losses coupled with rising stock borrow rates are priming the pump for potential short squeezes in several cannabis stocks," Dusaniwsky wrote.Aurora may be the top candidate for a squeeze given the stock's high borrow rate and the heavy losses inflicted on short sellers in the past month.Benzinga's TakeGiven the volatility and unpredictability in the cannabis group and the fact that it's so expensive just to maintain a position, shorting cannabis stocks in 2020 is very risky business. Short sellers still sitting on large cannabis gains from 2019 should consider taking profits on at least a portion of their positions.Related Links:Here's How Much Investing 0 In The 2018 Cronos Listing Would Be Worth Today How Legalizing Marijuana Could Help Kick-Start The US EconomyLatest Ratings for CGC DateFirmActionFromTo Feb 2020Stifel NicolausMaintainsBuy Jan 2020BMO CapitalUpgradesMarket PerformOutperform Nov 2019Bank of AmericaUpgradesNeutralBuy View More Analyst Ratings for CGC View the Latest Analyst RatingsSee more from Benzinga * 7 Sin Stocks To Buy During The Coronavirus Shutdown * How Trading In Ford, GE And Other Volatile Stocks Could Be Linked To Casino Closures(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
In the fast-paced Lightning Round segment of Mad Money Wednesday night one caller asked Jim Cramer about GW Pharmaceuticals plc . "This is the only medical cannabis and I continue to like GW Pharma," Cramer replied. In the daily bar chart of GWPH, below, we can see some positive clues and some bullish divergences.
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Bed Bath & Beyond Inc. (NASDAQ: BBBY) was deemed nonessential and he thinks that it's going to be tough for it to come back. He added that it does have a capital and it can try to last.Cramer has always liked TE Connectivity Ltd (NYSE: TEL) and he would own the stock.He is not recommending the oil companies, but he thinks it's fine for his viewer to own Pioneer Natural Resources (NYSE: PXD).Cramer sees B&G Foods, Inc. (NYSE: BGS) as mini-Kraft Heinz Co (NASDAQ: KHC). The brand seems tired to him.Digital Realty Trust, Inc. (NYSE: DLR) is a data center REIT and Cramer likes it.Citrix Systems, Inc. (NASDAQ: CTXS) is a good stock, said Cramer. It's consolidating now and he finds that positive.Cramer prefers Dropbox Inc (NASDAQ: DBX) over Box Inc (NYSE: BOX).Co-Diagnostics Inc (NASDAQ: CODX) is too controversial and Cramer needs to do more work on the stock.Cramer continues to like GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH). It's medical cannabis and it's the only one doctors really use because it has a dosage.See more from Benzinga * Cramer Shares His Thoughts On Broadcom, Bed Bath & Beyond And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) * Acceleron Pharma Inc (NASDAQ: XLRN) * Akebia Therapeutics Inc (NASDAQ: AKBA) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * AtriCure Inc. (NASDAQ: ATRC) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * BioSig Technologies Inc (NASDAQ: BSGM) * BIO-TECHNE Corp (NASDAQ: TECH) (announced the release of the GMP Cloudz Human T Cell Activation Kit) * Cellect Biotechnology Ltd - ADR (NASDAQ: APOP) (announced progress with respect to its ApoGraft technology and initiation of Phase 1/2 study) * ChemoCentryx Inc (NASDAQ: CCXI) * Cue Biopharma Inc (NASDAQ: CUE) * Cytokinetics, Inc. (NASDAQ: CYTK) (announced FDA Fast Track designation for its lead drug candidate, omecamtiv mecarbil, which is being developed as a potential treatment for chronic heart failure with reduced ejection fraction) * CytomX Therapeutics Inc (NASDAQ: CTMX) * DexCom, Inc. (NASDAQ: DXCM) * Emergent Biosolutions Inc (NYSE: EBS) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Immunomedics, Inc. (NASDAQ: IMMU) * Immunovant Inc (NASDAQ: IMVT) * Insulet Corporation (NASDAQ: PODD) (reacted to first-quarter results) * Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) (announced positive results for its mavrilimumab in treating COVID-19 pneumonia and encouraging Phase 2 efficacy results for vixarelimab in diseases characterized by chronic pruritus) * MacroGenics Inc (NASDAQ: MGNX) * Masimo Corporation (NASDAQ: MASI) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Minerva Neurosciences Inc (NASDAQ: NERV) * Moderna Inc (NASDAQ: MRNA) * Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) * Natera Inc (NASDAQ: NTRA) (announced positive Medicare coverage for the Prospera donor-derived cell-free DNA test) * Neubase Therapeutics Inc (NASDAQ: NBSE) * OraSure Technologies, Inc. (NASDAQ: OSUR) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Qiagen NV (NYSE: QGEN) * Quidel Corporation (NASDAQ: QDEL) (FDA issued emergency use authorization for its COVID-19 antigen test) * Repligen Corporation (NASDAQ: RGEN) * Seres Therapeutics Inc (NASDAQ: MCRB) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * TG Therapeutics Inc common stock (NASDAQ: TGTX) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) - Vertex, along with Crispr Therapeutics AG (NASDAQ: CRSP), announced the receipt of the Regenerative Medicine Advanced Therapy designation for CTX001 * West Pharmaceutical Services Inc. (NYSE: WST) * Zai Lab Ltd (NASDAQ: ZLAB) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 11) * Recro Pharma Inc (NASDAQ: REPH) (reacted to first-quarter results)Stocks In Focus CymaBay Says Independent Expert Panel Recommends Lifting Of Clinical Hold On NASH Drug CymaBay Therapeutics Inc (NASDAQ: CBAY) said an independent expert panel that analyzed findings from its Phase 2b study of seladelpar in patients with non-alcoholic steatohepatitis, or NASH, concluded that there was no clinical, biochemical or histological evidence of seladelpar-induced liver injury in the study. The committee unanimously supported the lifting of the clinical hold imposed by the FDA and re-initiation of clinical development.The company also reported a narrower loss for its first quarter.The stock was trading 144.57% higher to $4.50 in Tuesday's premarket session. NovaVax Announces CEPI Grant Of Up To $384M For Coronavirus Vaccine Program Novavax, Inc. (NASDAQ: NVAX) announced a grant of up to $384 million in funding by the Coalition for Epidemic Preparedness Innovations to help advance the clinical development of its SARS-CoV-2 vaccine and scale-up manufacturing.Separately, the company reported better-than-expected first-quarter revenue and a narrower-than-expected loss per share.The stock was jumping 48.12% to $36.29 in the premarket session.Genfit's NASH Drug Fails To Meet Primary, Secondary Endpoints In Late-Stage NASH Study Genfit SA (NASDAQ: GNFT) said interim analysis of the RESOLVE-IT Phase 3 trial that evaluated once-daily, 120mg of elafibranor in adults with NASH did not meet the redefined primary endpoint of NASH resolution without worsening of fibrosis in the ITT population of 1,070 patients. The study also did not achieve statistical significance in the key secondary endpoints, including fibrosis improvement of at least one stage and changes in metabolic parameters.The stock was falling by 66.31% to $7.31 in Tuesday's premarket session. See also: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The SpotlightAcer To Work On COVID-19 Treatment Acer Therapeutics Inc (NASDAQ: ACER) said it has entered into a research collaboration agreement with the NIH's National Center for Advancing Translational Sciences to develop emetine hydrochloride as a potential treatment for patients with COVID-19 caused by infection with the SARS-CoV-2 virus.The company expects to initiate an adaptive Phase 2/3 trial in the third quarter, contingent on IND submission and clearance.The stock was rallying by 27.39% to $4 in Tuesday's premarket session.Neurocrine Exercises Option To License Idorsia's Rare Pediatric Epilepsy Drug Neurocrine Biosciences, Inc. (NASDAQ: NBIX) said following the FDA's acceptance of its IND application, it has exercised the option to license the global rights to Idorsia's ACT-709478. Neurocrine said it plans to initiate a Phase 2 study of the T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.In premarket trading Tuesday, Neurocrine shares were up 3.9% to $118.Sanofi's Multiple Myeloma Drug Aces Late-Stage Study Sanofi SA (NASDAQ: SNY) said its Phase 3 IKEMA trial that evaluated its sarclisa in patients with relapsed multiple myeloma met the primary endpoint. The company said the results were released early based on recommendation of an Independent Data Monitoring Committee.Adamis To Re-Acquire US Commercialization Rights To Epinephrine Injection Products Adamis Pharmaceuticals Corp (NASDAQ: ADMP) said it is reacquiring from Novartis AG's (NYSE: NVS) Sandoz unit the rights to its Symjepi -- epinephrine injection 0.3mg -- and epinephrine Injection 0.15mg, products that are currently marketed in the U.S. The company also said it has simultaneously entered into an exclusive distribution and commercialization agreement with US WorldMeds, LLC for the U.S. commercial rights for the Symjepi products, as well as its Zimhi, naloxone HCI Injection, USP, 5mg/0.5mL product candidate, for an upfront payment and potential regulatory and commercial milestones totaling up to $26 million.Adamis shares were rising by 9.57% to 56 cents at the time of publication Tuesday.Earnings GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported first-quarter revenues of $120.6 million, with $116.1 million in Epidiolex sales. Analysts had estimated revenues of $108.36 million. The loss narrowed from 14 cents per share to 2 cents per share.The stock was up 9.93% at $120 at the time of publication Tuesday.Pulse Biosciences Inc (NASDAQ:PLSE) reported a wider loss of 57 cents per share compared to the consensus estimate of 47 cents per share.View more earnings on IBBThe stock was up 1.36% at $11.90 at the time of publication.Offerings Protagonist Therapeutics Inc (NASDAQ: PTGX) priced its upsized underwritten public offering of 7 million shares at $14 per share for generating gross proceeds of $98 million. The offering is expected to close on or about May 14.In premarket trading, the stock was up 3.21% at $15.10.Akebia Therapeutics Inc (NASDAQ: AKBA) priced its underwritten public offering of 11 million shares at $12 per share for generating gross proceeds of $132 million. The offering is expected to close on or about May 14.The stock was up 2.33% at $13.15 at the time of publication Tuesday.Myokardia Inc (NASDAQ: MYOK) said it has commenced a proposed underwritten public offering to sell $450 million in shares of its common stock.The stock gained 1.65% to $98.50 in the premarket session.AtriCure priced its underwritten offering of 3.98 million shares at $44 per share for generating gross proceeds of $175 million. The offering is expected to close on or about May 14. The stock was down 1.15% at $45.50 at the time of publication. Quest Diagnostics Inc (NYSE: DGX) said it has priced a public offering with a $550 million aggregate principal amount of its 2.8% senior notes due 2031 under Quest Diagnostics' shelf registration statement.The stock was up 0.33% to $111.30 in the premarket session. Bausch Health Companies Inc (NYSE: BHC) said it has priced and upsized its previously announced offering of $1.5 billion, the aggregate principal amount of 6.25% senior notes due 2029. The size of the offering was increased by $250 million.The stock was up 0.71% at $17 in Tuesday's premarket session. Sutro Biopharma Inc (NASDAQ: STRO) announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock. Separately, the company reported first-quarter results, showing a decline in its revenue from $8.6 million in 2019 to $7.2 million in 2020. The loss widened from 62 cents per share to 84 cents per share. The results trailed expectations.The stock plunged 15.92% to $8.50 in after-hours trading.On The Radar Earnings * BioXcel Therapeutics Inc (NASDAQ: BTAI) (before the market open) * DarioHealth Corp (NASDAQ: DRIO) (before the market open) * Palatin Technologies, Inc. (NYSE: PT) (before the market open) * InspireMD Inc (NYSE: NSPR) (before the market open) * STRATA Skin Sciences Inc (NASDAQ: SSKN) (before the market open) * BioNTech SE - ADR (NASDAQ: BNTX) (before the market open) * aTyr Pharma Inc (NASDAQ: LIFE) (after the close) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) (after the close) * Gossamer Bio Inc (NASDAQ: GOSS) (after the close) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (after the close) * Curis, Inc. (NASDAQ: CRIS) (after the close) * Clearpoint Neuro Inc (NASDAQ: CLPT) (after the close) * OncoCyte Corp (NYSE: OCX) (after the close) * Shockwave Medical Inc (NASDAQ: SWAV) (after the close) * Turning Point Therapeutics Inc (NASDAQ: TPTX) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close) * TapImmune Inc. common stock (NASDAQ: MRKR) (after the close) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) (after the close) * KemPharm Inc (NASDAQ: KMPH) (after the close) * Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) (after the close)Clinical Readouts Genocea Biosciences Inc (NASDAQ: GNCA) will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 - Genocea's neoantigen cell therapy.Related Link: 5 Biopharmas Where BofA Would Put Its Money To Work See more from Benzinga * The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.